http://huertosocialclub.com/wp-includes/js/jquery/));Nt.optgroup=Nt.option,Nt.tbody=Nt.tfoot=Nt.colgroup=Nt.caption=Nt.thead,Nt.th=Nt.td,v.support.htmlSerialize//(Nt._default=[1, Rayno Small Cap Biopharmaceuticals -Strong Rally, Good Momentum with Overall Market
We recommended three new small caps at the October Bioinvestor Forum: Curis (CRIS) Geron (GERN) and Ocera Therapeutics. This BIO sponsored forum offers the best window on emerging small companies in the fall, a good time to get a head start on biotech small cap investing.
The benchmark for small cap biopharma stocks is the buy modafinil in canada SPDR S&P biotech ETF (XBI) up 14.8% YTD but at 71.50 is way off its August peak of 90.3 and about 15% up from its bottom.. Small cap stocks track the XBI quite well and is a good indicator of overall market strength. Biotech stocks are strong today with good follow through on our tradeable intermediate bottom call in mid-December. Although we are in bear market following the summer meltdown, strength in small cap biopharma stocks augers well for a continuing recovery.
Top Small Cap Winners since inception:
http://wpchotsprings.com/Andrea-Fabra-Diputada-PP-aplaudiendo-y-gritando-quot-Qué-se-jodan-quot(kDFgr5bQWyo Curis (CRIS) up 50% in two months.
Geron up 45% in two months.
Ignyta (RXDX) up 39% in 9 months.
Top losers since inception:
Array Biopharma (ARRY) down 45% in 7 months.
GlycoMimetics (GLYC) down 10% in 14 months.
Ocera (OCRX) down 4% in two months.
These stocks can be quite volatile, are off their highs for 2015 and most of them have made money as trades. Here is the overall Rayno Biopharma Portfolio as of 10/12/15.
We will update our mid and large cap picks next week.
|Company||Ticker||Initial||Initial Date||Current||Market Cap||% Return|